A number of other equities analysts have also weighed in on the company. Wedbush lifted their price objective on Voyager Therapeutics from $27.00 to $36.00 and gave the company an outperform rating in a research note on Tuesday, June 18th. Morgan Stanley raised their target price on Voyager Therapeutics from $21.00 to $28.00 and gave the company an equal weight rating in a research report on Friday, July 12th. Nomura raised their target price on Voyager Therapeutics from $26.00 to $37.00 and gave the company a buy rating in a research report on Thursday, June 20th. Finally, HC Wainwright restated a buy rating and set a $22.00 target price on shares of Voyager Therapeutics in a research report on Monday, May 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Voyager Therapeutics presently has a consensus rating of Buy and a consensus price target of $27.00.
Shares of NASDAQ VYGR traded down $0.15 during trading on Wednesday, reaching $20.53. 777,380 shares of the company traded hands, compared to its average volume of 355,879. The company has a fifty day moving average price of $24.74. The firm has a market cap of $753.22 million, a PE ratio of -7.47 and a beta of 2.55. Voyager Therapeutics has a 12-month low of $7.76 and a 12-month high of $28.79.
Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its holdings in Voyager Therapeutics by 4.2% in the 4th quarter. Bank of New York Mellon Corp now owns 88,459 shares of the company’s stock worth $831,000 after buying an additional 3,543 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Voyager Therapeutics by 23.1% during the 4th quarter. Geode Capital Management LLC now owns 287,264 shares of the company’s stock worth $2,700,000 after purchasing an additional 53,888 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Voyager Therapeutics by 211.0% during the 4th quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock worth $100,000 after purchasing an additional 7,217 shares during the last quarter. D. E. Shaw & Co. Inc. acquired a new position in shares of Voyager Therapeutics during the 4th quarter worth approximately $370,000. Finally, Squarepoint Ops LLC boosted its holdings in shares of Voyager Therapeutics by 131.7% during the 4th quarter. Squarepoint Ops LLC now owns 34,983 shares of the company’s stock worth $329,000 after purchasing an additional 19,883 shares during the last quarter. Hedge funds and other institutional investors own 73.92% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Featured Story: Fundamental Analysis and Individual Investors
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.